Cantor Fitzgerald Issues Negative Estimate for ARWR Earnings

Key Points

• Cantor Fitzgerald has revised its earnings estimates for Arrowhead Pharmaceuticals, lowering the FY2025 EPS prediction from ($0.54) to ($0.94), while the consensus for the current full-year earnings is ($2.42) per share.
• Arrowhead Pharmaceuticals recently reported a quarterly earnings miss with an EPS of ($1.26), falling short of the consensus estimate by $0.32, along with revenue also below expectations at $27.77 million.
• Despite the earnings downgrade, two previous analysts' ratings maintain a "Strong Buy," and the company has a current consensus rating of "Buy" with a target price of $43.14.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Cantor Fitzgerald decreased their FY2025 earnings estimates for Arrowhead Pharmaceuticals in a report issued on Wednesday, September 10th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biotechnology company will post earnings per share of ($0.94) for the year, down from their prior forecast of ($0.54). The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. Cantor Fitzgerald also issued estimates for Arrowhead Pharmaceuticals' FY2026 earnings at ($2.24) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The company had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same quarter in the prior year, the firm earned ($1.38) earnings per share.

Several other analysts have also issued reports on the stock. Chardan Capital reissued a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. B. Riley raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 2nd. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ ARWR traded up $0.75 during midday trading on Friday, hitting $29.42. The company's stock had a trading volume of 1,991,799 shares, compared to its average volume of 2,043,622. The stock has a fifty day moving average price of $20.23 and a 200 day moving average price of $16.59. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $31.13. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $4.07 billion, a price-to-earnings ratio of -22.98 and a beta of 1.00.

Institutional Trading of Arrowhead Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Virtus Advisers LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth approximately $34,000. GAMMA Investing LLC grew its stake in shares of Arrowhead Pharmaceuticals by 297.6% in the first quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 1,628 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth approximately $49,000. Nisa Investment Advisors LLC grew its stake in shares of Arrowhead Pharmaceuticals by 75.9% in the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 1,308 shares during the period. Finally, Daiwa Securities Group Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 883.3% in the second quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company's stock worth $66,000 after buying an additional 3,763 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 15,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $25.00, for a total value of $375,000.00. Following the completion of the transaction, the insider directly owned 247,122 shares of the company's stock, valued at approximately $6,178,050. The trade was a 5.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 25,000 shares of company stock valued at $575,000 over the last three months. 4.30% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.